Sign in
CompletedPhase 3

A Study of Olezarsen (ISIS 678354) Administered to Participants With Severe Hypertriglyceridemia.

Key facts

Who runs it
Ionis Pharmaceuticals Inc.
Where
Bulgaria, Czechia, Denmark, Finland, France, Germany, Hungary, Italy, Netherlands, Norway, Poland, Portugal, Slovakia, Spain, and Sweden85 sites in 15 countriesChoose a country to see its sites
Trial code
  • 2021-002192-19
  • 2024-510696-38-00
  • NCT05681351
  • U1111-1302-3919
Status
Completed
Phase
Phase 3
People taking part
368 people enrolled
Started
8 Mar 2022
Ended
28 May 2025
Type of study
Interventional
Record updated
30 June 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Fasting TG ≥ 500 mg/dL (5.65 mmol/L) at Screening and Qualification
  • Patients must be on lipid-lowering therapy that should adhere to standard of care (SOC) per local guidelines. Lipid-lowering medications should be optimized and stabilized for at least 4 weeks prior to Screening to minimize changes in these medications during the study
  • 18 Years and older (Adult, Older Adult)

Who cannot take part

  • Hemoglobin A1c (HbA1c) ≥ 9.5% at Screening
  • Total bilirubin > upper limit of normal unless due to Gilbert's syndrome
  • Alanine aminotransferase or aspartate aminotransferase > 3.0 × upper limit of normal

This trial has no sites in United States.

It has sites in 15 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

To evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting TG from Baseline.

Data and sources

Registry record
How to verify a trial in the registry
Official title
ISIS 678354-CS5: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of ISIS 678354 Administered Subcutaneously to Patients with Severe Hypertriglyceridemia.
Record updated
30 June 2025